KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 --

Read more at globenewswire.com